Fig. 6

The effects of Afatinib on the EGFR/ERK1/2 /c-Jun pathway and the expression of PD-L1. Western blot was used to analyze the expression and phosphorylation level of EGFR/ERK1/2/c-Jun pathway and PD-L1 expression in (a) ES2 and (b) OVCAR-3 EX after Afatinib (0 μmol/l, 2 μmol/l, 4 μmol/l, and 6 μmol/l) treatment. The transwell chamber was used to detect the migration and invasion ability of (c) ES-2 and (d) OVCAR-3 EX cells after Afatinib (0 μmol/l, 2 μmol/l, 4 μmol/l, and 6 μmol/l) treatment. PD-L1 mRNA and protein levels in the four ovarian cancer cell lines were detected by RT-qPCR (e) and western blot (f). Magnification × 200. *p < 0.05, **p < 0.01, or***P < 0.001